What is Helico Bio?
Helico Bio, established in 2020 in Auckland, New Zealand, is a biotechnology firm founded by plant and computational scientists. The company's core mission is to accelerate the research and development of medicines for underserved populations by integrating in silico predictions with wet lab experiments. This innovative approach aims to expedite the introduction of their plant-based models to the global market, positioning Helico Bio at the forefront of pharmaceutical R&D innovation.
How much funding has Helico Bio raised?
Helico Bio has raised a total of $1.3M across 1 funding round:
Angel/Seed
$1.3M
Angel/Seed (2022): $1.3M with participation from Icehouse Ventures and Custos Privatestiftung
Key Investors in Helico Bio
Icehouse Ventures
Icehouse Ventures is a prominent venture capital firm in New Zealand, managing significant assets and focusing on early-stage companies. With a history dating back to 2003, they actively support Kiwi innovators and have a broad network of over 900 investors.
Custos Privatestiftung
Custos Privatestiftung is an investment entity that has participated in Helico Bio's funding rounds. Further details on their specific investment focus are not publicly available, but their involvement suggests a strategic interest in the biotechnology sector.
What's next for Helico Bio?
The recent major strategic investment signals a pivotal growth phase for Helico Bio. This capital infusion is expected to fuel the expansion of its research initiatives, potentially enabling the company to scale its operations and advance its pipeline of novel therapeutics. The focus on integrating computational science with biological experimentation suggests a strategic direction towards optimizing drug discovery processes and bringing much-needed medicines to market more efficiently.
See full Helico Bio company page
